Tirzepatide peptide UK: Mounjaro and the law
This tirzepatide UK peptide law guide covers lawful supply, NHS access through NICE, private prescribing, counterfeit pen risk, and the grey market in unlicensed tirzepatide. Tirzepatide is a UK-licensed prescription-only medicine, marketed as Mounjaro.
What tirzepatide is
Tirzepatide is a synthetic peptide — a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist that activates both receptors at once. In the UK it is marketed as Mounjaro. The licensed indications are set out in the marketing authorisation and Summary of Product Characteristics. Tirzepatide is licensed for type 2 diabetes and, separately, for weight management, and NICE has appraised it for both.
Licensed dose range
Tirzepatide is titrated upward from a low starting dose to a maximum licensed dose of 15 mg, injected once weekly — see our weight loss injections guide for the wider dosing and eligibility picture across Wegovy, Mounjaro, and Saxenda. This is separate from the “research” dosing sometimes discussed for unlicensed compounds, which has no basis in the approved prescribing information.
NHS access
NHS access depends on NICE guidance and the specific service. NICE has issued technology appraisal guidance covering tirzepatide for weight management; check the current NICE position rather than assuming eligibility. Local commissioning of specialist weight-management services affects practical access.
Private access
Private prescribing in the UK is lawful when carried out by a registered prescriber after an appropriate clinical assessment, with dispensing by a UK-regulated pharmacy. Online private services vary in quality of clinical assessment. A 30-second questionnaire that produces a prescription is not the same as a clinical consultation.
Verified purchase routes and grey-market compounds
Tirzepatide can only be lawfully purchased in the UK through a verified pharmacy — registered with the GPhC in England, Scotland and Wales, or the PSNI in Northern Ireland — after assessment by a registered prescriber — see our guide to checking a UK pharmacy. Grey-market “research-grade” compounds sold outside that route have no independent laboratory verification of purity, strength, or the pharmaceutical-grade manufacturing standards a licensed medicine is held to, and there is no MHRA-approved generic or compounded version of tirzepatide at the time of writing.
Counterfeit and grey market
Demand has driven a significant grey market in counterfeit and unregulated tirzepatide product, both as pens and as “research” vials. The MHRA has warned about counterfeit GLP-1 / GIP products. The risks are the same as for counterfeit semaglutide: unknown identity, dose, sterility, and provenance, with documented cases of harm.
Tirzepatide vs retatrutide
Retatrutide is sometimes marketed alongside tirzepatide as a “next-generation” research peptide. Unlike tirzepatide, retatrutide has no UK marketing authorisation anywhere — it remains an investigational drug. See our retatrutide UK legal status guide for that separate, unlicensed framing.
Red-flag claims
If you see wording like this on a seller, clinic, or social-media advert, treat it as a warning sign rather than a benefit.
“Mounjaro without prescription, UK delivery”
Tirzepatide is a UK POM. Supply without prescription is not lawful UK supply.
“Generic tirzepatide — same as Mounjaro”
There is no licensed generic equivalent at the time of writing. 'Generic tirzepatide' is almost always grey-market product.
“Compounded tirzepatide”
UK compounding is narrowly framed and not a workaround for unlicensed peptide supply.
“Vials of tirzepatide for research use”
Sold to consumers who are not researchers, marketed alongside weight-loss claims — the contradiction the MHRA looks at.
Sources & further reading
- MHRA — gov.uk
- NICE TA1026 — tirzepatide for managing overweight and obesity — nice.org.uk
- MHRA Drug Safety Update (publication landing) — gov.uk
Filter by therapeutic area for GLP-1 / counterfeit pen alerts.
- NHS — obesity treatment (references Mounjaro) — nhs.uk
- Yellow Card — yellowcard.mhra.gov.uk
- WADA Prohibited List — wada-ama.org
Frequently asked questions
- Is tirzepatide legal in the UK?
- Yes — tirzepatide (brand name Mounjaro) is a UK licensed prescription-only medicine. Lawful supply requires a UK prescription and a regulated dispensing pharmacy.
- Can I get Mounjaro on the NHS?
- NHS access depends on NICE guidance and local commissioning. Some weight-management pathways now include tirzepatide; eligibility criteria are specific and change over time. Check current NICE position.
- Is tirzepatide a peptide?
- Tirzepatide is a dual GIP / GLP-1 receptor agonist — a synthetic peptide, yes. It is structurally and pharmacologically distinct from semaglutide.
- Is buying tirzepatide online without a prescription legal?
- Not lawfully through a UK route. Any seller offering tirzepatide without a prescription is outside the UK regulatory framework. Product authenticity, dose accuracy, and supply chain are unverified.
- Is 'research only' tirzepatide a sensible alternative?
- Marketing labels do not change UK regulatory framing. 'Research only' tirzepatide is grey-market product whose identity, purity, and dose accuracy are unverifiable. We do not consider it a sensible alternative to the lawful route.
- Is tirzepatide on the WADA Prohibited List?
- Athletes must verify current WADA / UKAD status directly. GLP-1 / GIP receptor agonist status can change; strict liability applies.